financetom
Business
financetom
/
Business
/
Moody's Secular Growth Trends Seen as Intact Despite Macro Challenges, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Moody's Secular Growth Trends Seen as Intact Despite Macro Challenges, RBC Says
May 27, 2025 8:33 AM

11:08 AM EDT, 05/27/2025 (MT Newswires) -- Moody's (MCO) secular growth trends are intact despite near-term macroeconomic difficulties, RBC Capital Markets said in a note Monday.

Citing Moody's Chief Financial Officer Noemie Heuland, RBC said lending solutions, know-your-customer, insurance risk platforms and private credit continue to be strong.

"Additionally, the shift toward solution-based selling presents significant cross-sell opportunities within banking, as it enables holistic, end-to-end solutions," the note said.

RBC also said that separately, corporate has "meaningful" growth potential that has yet to be tapped.

RBC maintained the company's outperform rating and $550 price target.

Shares of Moody's were up 1.7% in recent trading Tuesday.

Price: 477.53, Change: +7.88, Percent Change: +1.68

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Anthropic's valuation more than doubles to $183 billion after $13 billion fundraise
Anthropic's valuation more than doubles to $183 billion after $13 billion fundraise
Sep 2, 2025
Sept 2 (Reuters) - Artificial-intelligence company Anthropic said on Tuesday it is now valued at $183 billion post-money, over twice as much as its earlier valuation, as investor enthusiasm towards AI startups stays strong despite some doubts over tech industry spending. The new valuation is a jump from the $61.5 billion post-money valuation in March this year, where it raised...
This Merck Pill Promises Powerful Cholesterol Reduction Without Injections
This Merck Pill Promises Powerful Cholesterol Reduction Without Injections
Sep 2, 2025
Merck & Co. Inc. ( MRK ) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance). Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL cholesterol levels in the blood....
Outlook Therapeutics Requests Meeting With US FDA Regarding Complete Response Letter for ONS-5010
Outlook Therapeutics Requests Meeting With US FDA Regarding Complete Response Letter for ONS-5010
Sep 2, 2025
01:38 PM EDT, 09/02/2025 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Tuesday it submitted a Type A meeting request to the US Food and Drug Administration to discuss a complete response letter for a biologics license application resubmission for ONS-5010, an investigational treatment for wet macular degeneration. The company said it has requested a meeting as it seeks...
Nauticus Robotics to Implement 1-for-9 Reverse Stock Split
Nauticus Robotics to Implement 1-for-9 Reverse Stock Split
Sep 2, 2025
01:35 PM EDT, 09/02/2025 (MT Newswires) -- Nauticus Robotics ( KITT ) said Tuesday it will implement a one-for-9 reverse stock split of its common stock effective Friday, following approval by its board and stockholders. The split-adjusted shares will begin trading on the Nasdaq Capital Market on Friday and is intended to increase its share price to comply with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved